1.Prevalence of occult hepatitis B virus infection among blood donors in Ulaanbaatar city, 2013
Tserendejid M ; Naranchimeg L ; Erdenebayar N
Mongolian Medical Sciences 2015;172(2):10-13
remains the most frequent transfusion-transmitted viral infection; thus, the term occulthepatitis B virus infection (OBI) was introduced. OBI is simply defined as serologically undetectable hepatitis Bsurface antigen (HBsAg-ve), despite the presence of circulating HBV DNA with or without the presence of HBVantibodies.GoalTo determine the prevalence of occult hepatitis B among blood donors and evaluate the presence of HBV DNAin HBsAg negative plasma samples.Materials and MethodsIt includes 16700 samples which donated in NCTM in Ulaanbaatar in 2013. We used to “triplex” PCR assay thatincluded the detect of hepatitis B virus HBV-DNA in addition HCV-RNA and HIV1/2-RNA for whom with absenceof serological markers of infection. The studies used molecular biology methods were performed with the help ofequipment (ROCHE COBAS S 201) and technology based on Real Time PCR (pool size: 6 donation) Then wechoose HBsAg negative, DNA positive samples and determined, anti-HBc and anti-HBs by serological methods,of ELISA Wantai HBc and HBs 3.0 tests.ResultsThe 14948 samples were detected serological negative in the total of 16700 samples. PCR test results show 35(0.23%) positive by HBV-DNA 29 (82.9%) of the 35 DNA positive blood donors were alone anti-HBc positive and3 (8.6 %) were anti-HBs, anti-HBc positive. 7(17.1%) were seronegative. Of the 35 OBI cases, 28 (80%) weredetected the first time they were screened for HBV DNA while 7 (20%) gave one more HBV PCR-nonreactiveresults before detection. Callback studies we determined 2 cases were pre-HBsAg window period.Conclusion:The prevalence of HBV DNA positive in HBsAg negative blood donors is found 0.2%. HBV NAT needs eitherextreme sensitivity or to be performed on individual donations to eliminate HBV DNA-containing units.
2.Results of screening for cytomegalovirus infection among blood donors in Ulaanbaatar, Mongolia
Tsogbadrakh B ; Naranchimeg L ; Erdenebayar N ; Munkhbayarlakh S
Mongolian Medical Sciences 2015;172(2):7-9
Background. Most people infected with Cytomegalovirus (CMV) have no signs or symptoms, but newborns andpeople with weakened immune systems are more at risk of developing signs and symptoms. CMV remains in thebody throughout a lifetime. Infected people may spread infection.Goal. The main aim of this study is to determine the prevalence of infection of cytomegalovirus (CMV) by enzymeimmunosorbent assay.Materials and Methods. In this study included subjects, age range of 17-60 years (total of 716) blood donorswho were served by the National center for transfusion medicine. Screening for Cytomegalovirus CMV IgG andIgM specific antibody concentrations determined using DIALAB ELIZA kits.Results. CMV-specific IgG antibodies were detected in 99.2% (710) of the studied subjects and, specific IgMantibodies in 0.1% (1). IgG antibodies positive individuals are compared to 4 blood groups and (p = 0.01) differencewas not statistically significant. IgG antibodies negative 6 individuals are included all in blood type B(III). IgMspecific antibodies positive (1) individual was in the age group 26-40 years, female and type of regular donor.Conclusion. We can conclude from our results of the determination of CMV IgG and IgM specific antibodiesshows that a number of risks of transfusion transmitted infection cytomegalovirus.
3.Attitude towards to blood donation among population, Mongolia, 2019
Oyuntsetseg D ; Suvd B ; Enkhjargal A ; Erdenebayar N
Mongolian Medical Sciences 2019;190(4):38-47
Background:
Blood is an important resource, both for planned treatments and urgent interventions. It can help
patients suffering from life-threatening conditions live longer and with a higher quality of life, and
supports complex medical and surgical procedures. According to WHO recommendation at least 1%
of the population of any country needs to donate their blood to accommodate the basic clinical needs
of the country. Accordingly, we aimed to assess existing attitudes of the general population towards on blood donors.
Materials and Methods:
The survey identified attitude of the population on blood donation and factors influencing them, using
quantitative and qualitative methods. The survey covered a population aged 18-60 years. SPSS
software version 21 was used for data analysis of the survey. The survey protocol and methodology
were reviewed and approved by the Scientific Committee at the NCPH. The Medical Ethical Committee
at the MOH reviewed the survey materials and issued an approval (2015/3).
Results:
The survey covered in total 3,782 people and there are 59.2% of surveyed respondents said they
have never thought of becoming a voluntary blood donor. Positive attitude on blood donation is
higher with statistical significance among women (59.0%), 18-25 years old (43.7%) and UB residents
citizens with higher education. As education level increases the number of respondents who thought
about donating blood is also increases. 16.1% of them had a history of blood donation before and
38.2% said they never thought about it. Twenty point four percent of respondents thought blood
donation brings some kind of risk. Nevertheless of the education level of surveyed respondents,
the percentage of answer blood donation is not risky for a person was the most common answer.
But respondent who is only literal and uneducated were don’t know about whether it has a risk or
not (385.37=2א, p=0.000001). Also, respondents failed to donate their blood because the family not
allowed, afraid, risk of infection, doesn’t want and had a busy schedule.
Conclusion
There is a high tendency to donate blood populations of young people aged 20-29, women, residents
of Ulaanbaatar, and uneducated and highly educated. The majority of respondents agreed that blood
donating is charity and a good deed. The leading causes of blood donation is the education, gender,
the desire of doing a good deed, peer influence and health condition.
4.The treatment of the leg deep vein thrombosis
Suvd S ; Gundegmaa Ts ; Baasanjav N ; Erdenebayar A
Mongolian Medical Sciences 2018;185(3):147-151
Thrombosis is a term for a blood clot occurring inside a blood vessel. R. Virchow postulated that
abnormalities in blood flow, hypercoagulability of the blood, and injury to the vessel wall are causally
related to thrombus formation. Many of the risk factors for deep vein thrombosis aretrauma for 9.3-
18.8%, birth for 16-17.3%, surgery for 14.3-30.3%, infection disease for 9.7-15.9%, cancer for 3.5%,
heart disease for 4.6% and 6.9-11.8% of deep vein thrombosis is an indistinct cause. Pain, swelling,
warmth, edema and redness in the affected leg are common symptoms.The diagnosis of deep vein
thrombosis of the leg can be difficult with clinical findings and history being unreliable. The National
Institute of Health and Care Excellence has evidence based recommendations on the prevention
and management of a wide range of health conditions. Here: incorporation of a clinical predication
score, D-dimer, and venous duplex ultrasound. The D-dimer blood test measures degraded fibrinogen, which is raised in patients with a clot. However, it cannot confirm deep vein thrombosis, as
D-dimer can be raised in other conditions including malignancy, infection, pregnancy, post-surgery,
inflammation, trauma, disseminated intravascular coagulopathy, and renal impairment. There are
two types venous ultrasound as the first line investigation for suspected deep vein thrombosis.
The aim of treatment for deep vein thrombosis are:
• The prevention of a thrombus progress
• Decrease the risk of the pulmonary embolism
• The reduction of the thrombus expansion or resolution.
• The prevention of the post thrombotic symptoms
• Decrease the mortality of vein thrombosis
Guidelines from NICE and ACCP recommended direct oral anticoagulants as first line treatment for
deep vein thrombosis. Direct oral anticoagulants include direct factor Xa inhibitors apixaban, rivaroxaban, and edoxaban, and a direct thrombin inhibitor dabigatron
5.Usage of blood and blood product
Oyuntsetseg D ; Enkhjargal A ; Erdenebayar N ; Suvd B ; Burmaajav B
Mongolian Medical Sciences 2020;193(3):47-53
Background:
A blood product is any therapeutic substance derived from human blood, including whole blood
and other blood components for transfusion, and plasma-derived medicinal products. Medicinal
(medical therapeutic) products derived from human donations of blood and plasma play a critical
role in health care. Safe, effective and quality-assured blood products contribute to improving and
saving millions of lives every year, as they: address child mortality and maternal health, dramatically
improve the life expectancy and quality of life of patients suffering from life-threatening inherited
disorders, such as haemophilia, thalassaemia and immune deficiency, and acquired conditions
such as cancer and traumatic haemorrhage and support complex medical and surgical procedures,
including transplantation. An insufficient or unsafe blood supply for transfusion has a negative impact
on the effectiveness of key health services and programmes to provide appropriate patient care in
numerous acute and chronic conditions. Ensuring access of all patients who require transfusion to
safe, effective and quality-assured blood products is a key component of an effective health system
and vital for patient safety.
Although the number of blood donors is increasing, there are still insufficient human and financial
resources for encouraging the growing demand of blood and blood products and new blood donors.
Material and Methods:
We collected secondary data by using using the order forms of hospitals that used blood and
blood products registered in the National Center for Blood Transfusion Research in 2017-2019 in
accordance with the retrospective survey method.
In total 34,119 hospital order information sheet was entered into computer in excel program, and
converted into SPSS 23 software, descriptive parameters were calculated and analyzed.
Results:
Compare to the 2017 (n=9076), the demand of blood product was increased by 21.8%, and 54.8%
in 2019. There are 51.9% (95%CI: 51.2-52.5) of total users are male, which is statistically significant.
The mean age of blood product users were aged 48.58±21.32, the youngest user was aged 1 and
the oldest age was 99. The demand of blood products were increased by growing of the age of users.
The product usage of age group of 46-55 was 17.8% and has trend to increase year by year. In
total, 11.3% of total blood product was utilized for children and 72.3% of them were aged less than 5
years old. 73.0% of total blood products were utilized in specialized hospitals, 14.6 % of them were
used in aimag and district level hospitals and 11.3% of them were used in private clinics. 24.4% of
blood products utilization was used for diseases of digestive system (К00-К93), 22.1% of them were
used for diseases of the blood and blood-forming organs and certain disorders involving the immune
mechanism, and 19.5% of them were used for the cancer (C00-C97) disease patient’s treatment.
Conclusion
Since after new treatment guidance was introduced the blood and blood products usage had been
increased.
6.ТӨМӨР ДУТАГДЛЫГ ЭРТ ИЛРҮҮЛЭХЭД РЕТИКУЛОЦИТЫН ГЕМОГЛОБИНЫГ ТОДОРХОЙЛОХЫН АЧ ХОЛБОГДОЛ
Purevjal O ; Erdenebayar N ; Munkhbayarlakh S ; Bolor A ; Oyunkhand Ts ; Odgerel Ts
Innovation 2017;11(2):49-51
BACKGROUND. Regular blood donation can lead to pre-clinical iron deficiency as well as iron deficiency anemia. With Each donation donors lose 220-250 mg of iron. Early detection of iron deficiency is important for the blood donors and even useful for blood and blood product safety and supply. The research work we studied present Ret-HE to be used to detect the occurrence of iron deficiency eritrony level. Purpose: The aim of this study was to determine Ret-He to have sensitivity and specificity for diagnosing iron deficiency than traditional iron measurements. Materials and methods: We performed a cross sectional and case control study of 156 blood donors who served National Center for Transfusion Medicine. Ret-He, hemoglobin, plasma iron and ferritin were measured using XN2000 Sysmex, and CobasE600 Roche. The statistical analysis was done using One way Anova, Rock curve, Kruskal Wallis test. Results: We examined 64(41.02%) male donors, 92(58.9%) female donors by measurements of Ret-He,hemoglobin, serum, iron and ferritin. Survey participants were 8.33%(n=13) with anemia, 91.67% (n=143) without anemia. In donors with anemia the results were: RBC 4.9*106 u/l, HGB 10.8 g/dl (10;11), serum ferritin 5.2 (4.3; 6.3) mmol, serum iron 4.5 (3.7; 5.8) mmol and Ret-He 25.5 (22; 26) pg. Donors were divided into 3 age groups: group I age was up to 25years, group II was between 26-35 years, group III age criteria was above 35. Group I had serum iron 13.5 (10.; 18.), serum ferritin 41.8 (14; 78), Ret-He 32.2 (30; 33.) RBC 5×106 u/l (4.6;5), HGB14.2g/dl (13.3;14. 2). Group II had serum iron 14.6 (11; 19), serum ferritin 54.1 μg/l (29; 138), Ret-He 32.2pg (31; 33), RBC 5.1×106 u/l(4.7;5.1), HGB14.8 g/dl (13.5;14.8),Group III had serum iron 15.1 umol/l (9; 20), serum ferritin 95.7 μg/l (39; 141), Ret-He 32.7pg (31; 34) , RBC4.9×106 u/l(4.6;4.9), HGB 14.5g/dl(13.8;14.5), respectively. According to a curve (Roc) analysis, AUC of serum iron was 0.0963, serum ferritin 0.909, Ret-He 0.975. The mean Ret-He was 32.3pg (31.3;33.4). The optimal cut off value for the Ret-He was 29,25pg by ROC analysis and are presented along with sensitivity 92.3% and specificity 95.1%. Conclusion: 1. Determining the amount of Ret-He has a better sensitivity and specificity for diagnosing iron deficiency compared to traditional iron measurements.
2. Ret-He has diagnostic indicators that are able to detect the depletion of iron reserves, erythron level. And it need to be used in further clinical practices, as well as doctors should be required to use it for diagnosis and treatment.
7.Evaluation of immunity rate against hepatitis B among workers in National Center for Transfusion Medicine
Tserendejid M ; Zayabileg A ; Tungalagtuya E ; Ganchimeg S ; Erdenebayar N
Health Laboratory 2020;12(2):11-14
Background:
Healthcare works are high risk of infection through occupational exposure that contact with blood and other body fluids, including infected person, uses needles, syringes, equipment or exposures to sharp instruments. The World Health Organization (WHO) estimates, approximately 66,000 health workers are infected with the hepatitis B virus (HBV) and 200-5000 workers arc infected with human immunodeficiency virus (HIV) each year due to carelessness. HBV infection is a global health problem that remains to preventive. Hepatitis B can be prevented by vaccines that are safe, available and effective. In our country, which has a high prevalence of hepatitis B virus infection, it has been concluded that the coverage of hepatitis B vaccination and the level of immunity of health workers are insufficient.
Aim:
To evaluate post vaccination immunity against HBV in the staff of National center for transfusion medicine
Methods:
63 workers with negative surface antigen of hepatitis B (HBsAg) and absent anamnesis of infection were selected for this study. In 2019 and 2020 all 63 workers were evaluated post vaccination immunity against HBV. Analysis done by Sysmex HSCL800 that is an automated immune assay system.
Results and discussion:
This center was begun to conduct the vaccination of workers from 2011. Among total 63 individuals involved in this study 53 (84.1%) were vaccinated against hepatitis B and 10 (15.9%) were not vaccinated. From the vaccinated 53 workers, 47 (88,7%) have immunized (anti-H Bs > 1 Ou/ml) but 6 (11.3%) of them were not immunized (anti-HBs <1 Ou/ml).
Therefore 1(1,9%) worker of them received just first dose, 14 (26.4%) workers were injected second dose, whereas 38 (71.7%) workers were vaccinated with third dose. The study shows that 12 (85.7%) workers after second dose and 34 (89.5%) workers after third dose were immunized.
Conclutions
As a result of hepatitis B vaccination, 88.7% of workers of the NCTM have had immunized against HBV. The final evaluation shows that 36 (57%) of workers had stable, 17 (27%) increased, and 10(16%) decreased level of immunization than the previous year.
8.Peripheral blood differential count of white blood cells in blood donor
Tsendsuren S ; Gansukh Ch ; Khongorzul T ; Enkhsaikhan L ; Erdenebayar N ; Nyambayar D ; Tsogtsaikhan S ;
Mongolian Medical Sciences 2020;193(3):3-10
Background:
Establishment of quantitative reference intervals of white blood cells and its subpopulations using
a high accuracy analytic system is essential for clinical medicine, public health, and anthropology.
We are unable to identify peer-reviewed literature sources describing white blood cell counts and
their subpopulations using monoclonal antibodies to specific surface antigens in healthy Mongolians.
This study aimed to measure the counts of white blood cells and their subpopulations in healthy
Mongolians using flowcytometry.
Materials and Methods:
The absolute number (cell/L) of leukocytes (CD45+), granulocytes, monocytes and lymphocytes were
measured by Magnetic Activated Cell Sorting Assay (MACSQuant Analyzer 10) in 287 blood donors
(158 males and 129 females) 17-64 years of age (mean age 33.1±12.4). Peripheral blood samples
were collected at the time of blood donation at the National Center for Transfusion Medicine.
Results
The mean values of leukocytes and granulocytes were lower in donors over 30 years of age (ANOVA:
F=4.408, p=0.002 and F=5.685, p=0.001) and regression analysis demonstrated indirect correlation
between counts of these cells and age of donors (r= - 0.198, p=0.001 and r=-0.221, p=0.001,
respectively). Gender-related differences in white blood cell counts were not found.
Mean value of lymphocyte count in donors investigated in spring (May and March, n = 87; 2224.6±775.3) was significantly higher than those in winter (December – February, n=180; 1613.2±454.3, p=0.001) and autumn (October, n=20; 1576.1±438.6, p= 0.001).
Comparing of our findings with the data from available literature shown that healthy Mongolians
have lower leukocyte count compared with Koreans, Chinese Han population and lower mean value
of lymphocyte count comparing with Korean, Chinese Han population, and Arabian (Saudi Arabia)
populations.